Dennis Bang Henriksen

SANOS Bioscience A/S is a Danish privately owned biotechnology company. Their business is to develop novel treatments for osteoporosis and other skeletal wasting diseases. It was founded in 2003 around patented and proprietary inventions from the Nordic Bioscience Group. This knowledge base includes a profound insight in the biology of skeletal tissue in health, molecular targets, biologicals, and lead compounds. SANOS is focused on the clinical development of SAN-134, an injectable formulation of the intestinal hormone glucagon-like peptide-2, GLP-2 for treatment of diseases with accelerated bone loss, such as osteoporosis. SANOS Bioscience A/S is headquarterd in Copenhagen, Denmark.

Coegin Pharma AS provides therapeutics that addresses inflammatory diseases. The company was founded by Berit Johansen on January 3, 2005 and is headquartered in Trondheim, Norway.

Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum.

Nordic Bioscience A/S engages in preclinical and clinical drug development. It specializes in precision medicine using biomarker technologies. The company was founded by Claus Henrik Christiansen and Bente Juel Riis in 1991 and is headquartered in Herlev, Denmark.

Verigen specializes in tissue engineering. Its cartilage repair technology involves harvesting knee cartilage cells that are cultivated in a laboratory before being transplanted into the knee. The operation is invasive and shorter than conventional treatment, with concomitant cost savings and outcomes